Showing 1 - 10 of 59
Empirical evidence demonstrates the value of intellectual property (IP) in creating economic growth, enhancing productivity and profitability, and increasing enterprise value. Research and Development (R&D) intensive industries, such as the life sciences, where patents are critical to...
Persistent link: https://www.econbiz.de/10005080978
Government support for partnering between BioPharma companies and universities is growing in the UK and some European countries but few studies have explored these partnerships.Through interviews and a survey of key institutions we explored perceptions of key informants on industry and...
Persistent link: https://www.econbiz.de/10005047502
No abstract received.
Persistent link: https://www.econbiz.de/10005050908
Multiple interacting factors influence the uptake and diffusion of medicines which are critical to improving health. However, there is a gap in our knowledge on how regulatory policies and other national health systems attributes combine to impact on the utilisation of innovative drugs, and...
Persistent link: https://www.econbiz.de/10005050909
Europe is currently experiencing the fastest rate of growth of HIV of any region of the world. An analysis of policy and health system responses to the HIV epidemic in Europe and central Asia (hereafter referred to as Europe) over the last 25 years reveals considerable heterogeneity. In general,...
Persistent link: https://www.econbiz.de/10005516738
Persistent link: https://www.econbiz.de/10005516874
Persistent link: https://www.econbiz.de/10005516880
Starting in the late 1980s, many Latin American countries began social sector reforms to alleviate poverty, reduce socioeconomic inequalities, improve health outcomes, and provide financial risk protection. In particular, starting in the 1990s, reforms aimed at strengthening health systems to...
Persistent link: https://www.econbiz.de/10012702806
A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs). The international agencies have forgotten pregnant women. Given the unacceptably high number of maternal and perinatal...
Persistent link: https://www.econbiz.de/10005341686
Persistent link: https://www.econbiz.de/10008345425